Приказ основних података о документу
Innovative and generic pharmaceuticals industry and drugs market
Inovativna i generička farmaceutska industrija i tržište lekova
dc.creator | Jovanović, Slobodanka | |
dc.creator | Matović, Danijela | |
dc.creator | Petrović, Slobodan | |
dc.date.accessioned | 2021-03-10T11:15:07Z | |
dc.date.available | 2021-03-10T11:15:07Z | |
dc.date.issued | 2010 | |
dc.identifier.issn | 0350-0373 | |
dc.identifier.uri | http://TechnoRep.tmf.bg.ac.rs/handle/123456789/1580 | |
dc.description.abstract | The pharmaceutical industry consists of two sectors: the innovative sector and generic sector. The innovative pharmaceutical industry is totally dependent on patents and these companies are focused on protecting against commodity and branded generics. Global pharmaceutical markets have experienced dramatic changes in recent years. The current global financial crisis is likely to hit pharmaceutical companies due to a lack of funding for research and production of many new drugs , while the national governments, concerned with the rising cost of pharmaceuticals within their national healthcare budgets, are striving to promote the use of generics over high-priced originator products. Serbia has the innovative generic pharmaceutical industry. . | en |
dc.description.abstract | Farmaceutsku industriju sačinjavaju dva sektora: inovativni i generički sektor. Inovativna farmaceutska industrija je u potpunosti zavisna od patenata i ove kompanije su fokusirane na zaštitu od generika (zaštićenih ili nezaštićenih žigom). Svetsko farmaceutsko tržište je pretrpelo dramatične promene poslednjih godina. Tekuća svetska finansijska kriza je izgleda pogodila farmaceutske kompanije zbog nedostatka fondova za istraživanje i proizvodnju mnogih novih lekova, dok nacionalne vlade obzirom na povećanje troškova lekova u okviru nacionalnog zdravstvenog budžeta, nastoje da promovišu generike u odnosu na skuplje originalne proizvode. Srbija ima inovativno - generičku industriju. | sr |
dc.publisher | Economics institute, Belgrade | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-sa/4.0/ | |
dc.source | Industrija | |
dc.subject | medicine | en |
dc.subject | innovative | en |
dc.subject | generic | en |
dc.subject | industry | en |
dc.subject | financial crisis | en |
dc.subject | lek | sr |
dc.subject | inovativna | sr |
dc.subject | generička | sr |
dc.subject | industrija | sr |
dc.subject | finansijska kriza | sr |
dc.title | Innovative and generic pharmaceuticals industry and drugs market | en |
dc.title | Inovativna i generička farmaceutska industrija i tržište lekova | sr |
dc.type | article | |
dc.rights.license | BY-SA | |
dc.citation.epage | 119 | |
dc.citation.issue | 1 | |
dc.citation.other | 38(1): 105-119 | |
dc.citation.rank | M24 | |
dc.citation.spage | 105 | |
dc.citation.volume | 38 | |
dc.identifier.rcub | https://hdl.handle.net/21.15107/rcub_technorep_1580 | |
dc.type.version | publishedVersion |
Документи
Датотеке | Величина | Формат | Преглед |
---|---|---|---|
Уз овај запис нема датотека. |